CRISPR Therapeutics
CRSP
447 hedge funds and large institutions have $3.47B invested in CRISPR Therapeutics in 2022 Q1 according to their latest regulatory filings, with 73 funds opening new positions, 170 increasing their positions, 97 reducing their positions, and 65 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 170 | Existing positions reduced: 97
12% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 65
10.25% more ownership
Funds ownership: 55.98% → 66.23% (+10%)
7% more capital invested
Capital invested by funds: $3.25B → $3.47B (+$222M)
0% more funds holding
Funds holding: 446 → 447 (+1)
4% less call options, than puts
Call options by funds: $149M | Put options by funds: $156M
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$290M |
| 2 |
BlackRock
New York
|
+$63.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$55.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.3M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$37.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$81.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$31.9M |
| 3 |
Jennison Associates
New York
|
-$31M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$28.5M |
| 5 |
Millennium Management
New York
|
-$21.4M |
CRSP Hedge Fund Activity: Q1 2022 in Review
447 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2022, worth a combined $3.47B — up 6.8% from $3.25B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new CRSP positions and 65 closed out — a net gain of 8 holders — while 170 added to existing stakes and 97 trimmed.
The largest buyer was Sumitomo Mitsui Trust Group, opening a new position worth an estimated $290M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $81.7M sold.
- 447 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2022, up from 446 in Q4 2021.
- Funds reported $3.47B of CRISPR Therapeutics stock for Q1 2022, up 6.8% quarter-over-quarter.
- 73 funds opened new CRISPR Therapeutics positions in Q1 2022 and 65 closed out, a net change of +8 holders.
- The largest CRISPR Therapeutics buyer in Q1 2022 was Sumitomo Mitsui Trust Group, an estimated $290M added.
- The largest CRISPR Therapeutics seller in Q1 2022 was EcoR1 Capital, an estimated $81.7M sold.
Based on aggregated 13F filings for Q1 2022.